Abstract:Infantile free sialic acid storage disease (ISSD) is a rare autosomal recessive metabolic disorder caused by a lysosomal membrane transport defect, resulting in accumulation of free sialic acid within lysosomes. Only a few cases have been described. We report on three new cases of ISSD with different modes of presentation: an infant with nephrotic syndrome, a case of fetal and neonatal ascites with heart failure, and a case of fetal ascites with esophageal atresia type III. From these patients and a review of … Show more
“…Determining whether this is the case will require analysis of a larger ethnic cohort and/or use of SNP-based linkage disequilibrium methods, beyond the scope of this report. The distribution of the observed storage material in our patients is similar to that reported previously (Lemyre et al 1999), and corresponds in a general sense to the expression pattern of sialin in the mouse (Yarovaya et al 2005).…”
Section: Discussionsupporting
confidence: 90%
“…We are aware of one earlier report of two children with free sialic acid storage and increased neuraminidase activity in lymphocytes, although activity was normal in fibroblasts in these same patients (Ylitalo et al 1986). In contrast, several authors have reported neuraminidase activity in ISSD patients as "normal" or "not decreased" (Baumk€ otter et al 1985;Paschke et al 1986;Pueschel et al 1988;Fois et al 1987;Nakano et al 1996;Lemyre et al 1999). Whether this apparent inconsistency represents true biological variation, differences in technique, or a chance observation due to the influence of other genetic modifiers is unclear at present.…”
Section: Discussionmentioning
confidence: 93%
“…Recently, SLC17A5 mutations have also been identified in children and adults with cerebral palsy-like chronic encephalopathy; thus, the recognized spectrum of clinical phenotypes continues to expand (Debray et al 2011;Mochel et al 2009Mochel et al , 2010. ISSD is situated at the opposite (severe) end of the SLC17A5 disease spectrum; cardinal features include profound developmental delay, failure to thrive, hepatosplenomegaly, coarse facies, hypopigmentation, and (typically) death in infancy (Lemyre et al 1999). Findings seen in a subset of cases include dysostosis multiplex, cardiomegaly, heart failure, and prematurity.…”
Infantile sialic acid storage disease (ISSD) is a lysosomal storage disease characterized by accumulation of covalently unlinked (free) sialic acid in multiple tissues. ISSD and Salla disease (a predominantly neurological disorder) are allelic disorders caused by recessive mutations of a lysosomal anionic monosaccharide transporter, SLC17A5. While Salla disease is common in Finland due to a founder-effect mutation (p.Arg39Cys), ISSD is comparatively rare in all populations studied.Here, we describe the clinical and molecular features of two unrelated Canadian Inuit neonates with a virtually identical presentation of ISSD. Both individuals presented antenatally with fetal hydrops, dying shortly following delivery. Urinary free sialic acid excretion was markedly increased in the one case in which urine could be obtained for testing; postmortem examination showed a picture of widespread lysosomal storage in both. Both children were homozygous for a novel splice site mutation (NM_012434: c.526-2A>G) resulting in skipping of exon 4 and an ensuing frameshift. Analysis of a further 129 pan-Arctic Inuit controls demonstrated a heterozygous carrier rate of 1/129 (~0.4 %) in our sample. Interestingly, lysosomal enzyme studies showed an unexplained ninefold increase in neuraminidase activity, with lesser elevations in the activities of several other lysosomal enzymes. Our results raise the possibility of a common founder mutation presenting as hydrops in this population. Furthermore, if confirmed in subsequent cases, the marked induction of neuraminidase activity seen here may prove useful in the clinical diagnosis of ISSD.
“…Determining whether this is the case will require analysis of a larger ethnic cohort and/or use of SNP-based linkage disequilibrium methods, beyond the scope of this report. The distribution of the observed storage material in our patients is similar to that reported previously (Lemyre et al 1999), and corresponds in a general sense to the expression pattern of sialin in the mouse (Yarovaya et al 2005).…”
Section: Discussionsupporting
confidence: 90%
“…We are aware of one earlier report of two children with free sialic acid storage and increased neuraminidase activity in lymphocytes, although activity was normal in fibroblasts in these same patients (Ylitalo et al 1986). In contrast, several authors have reported neuraminidase activity in ISSD patients as "normal" or "not decreased" (Baumk€ otter et al 1985;Paschke et al 1986;Pueschel et al 1988;Fois et al 1987;Nakano et al 1996;Lemyre et al 1999). Whether this apparent inconsistency represents true biological variation, differences in technique, or a chance observation due to the influence of other genetic modifiers is unclear at present.…”
Section: Discussionmentioning
confidence: 93%
“…Recently, SLC17A5 mutations have also been identified in children and adults with cerebral palsy-like chronic encephalopathy; thus, the recognized spectrum of clinical phenotypes continues to expand (Debray et al 2011;Mochel et al 2009Mochel et al , 2010. ISSD is situated at the opposite (severe) end of the SLC17A5 disease spectrum; cardinal features include profound developmental delay, failure to thrive, hepatosplenomegaly, coarse facies, hypopigmentation, and (typically) death in infancy (Lemyre et al 1999). Findings seen in a subset of cases include dysostosis multiplex, cardiomegaly, heart failure, and prematurity.…”
Infantile sialic acid storage disease (ISSD) is a lysosomal storage disease characterized by accumulation of covalently unlinked (free) sialic acid in multiple tissues. ISSD and Salla disease (a predominantly neurological disorder) are allelic disorders caused by recessive mutations of a lysosomal anionic monosaccharide transporter, SLC17A5. While Salla disease is common in Finland due to a founder-effect mutation (p.Arg39Cys), ISSD is comparatively rare in all populations studied.Here, we describe the clinical and molecular features of two unrelated Canadian Inuit neonates with a virtually identical presentation of ISSD. Both individuals presented antenatally with fetal hydrops, dying shortly following delivery. Urinary free sialic acid excretion was markedly increased in the one case in which urine could be obtained for testing; postmortem examination showed a picture of widespread lysosomal storage in both. Both children were homozygous for a novel splice site mutation (NM_012434: c.526-2A>G) resulting in skipping of exon 4 and an ensuing frameshift. Analysis of a further 129 pan-Arctic Inuit controls demonstrated a heterozygous carrier rate of 1/129 (~0.4 %) in our sample. Interestingly, lysosomal enzyme studies showed an unexplained ninefold increase in neuraminidase activity, with lesser elevations in the activities of several other lysosomal enzymes. Our results raise the possibility of a common founder mutation presenting as hydrops in this population. Furthermore, if confirmed in subsequent cases, the marked induction of neuraminidase activity seen here may prove useful in the clinical diagnosis of ISSD.
“…In a mild type of lysosomal free sialic acid storage, i.e., Salla disease common in Finland, newborns develop intellectual impairment gradually. In the more severe allelic variant, i.e., infantile free sialic acid storage disease (ISSD), patients generally die early in childhood or even in utero [2]. Individuals with symptoms of moderate severity are considered to have "intermediate severe Salla disease."…”
The allelic autosomal recessive lysosomal storage disorders Salla disease and infantile free sialic acid storage disease (ISSD) result from mutations in SLC17A5. This gene codes for sialin, a lysosomal membrane protein that transports the charged sugar, N-acetylneuraminic acid (sialic acid), out of lysosomes. ISSD has a severe phenotype with infantile onset, while the Finnish variant, Salla disease, has a milder phenotype with later onset. Both disorders cause developmental delay, and ISSD is generally fatal in early childhood. We describe a 30-month old non-Finnish, Caucasian child with global developmental delay of postnatal onset, language, and motor skills stagnant at a 3-4 month level, hypotonia, and mild but progressive coarsening of facial features. Urinary excretion of free sialic acid was elevated 4.5 times above control. EM of a skin biopsy revealed enlarged secondary lysosomes consistent with oligosaccharide storage. Free sialic acid in Wbroblasts was 3.8 § 0.9 nmol/mg protein (concurrent normal controls, 0.5 § 0.1); diVerential centrifugation indicated a lysosomal location. Genomic analysis revealed compound heterozygosity for two new SLC17A5 mutations. This child's clinical manifestations of a lysosomal free sialic acid storage disease are consistent with her sialin mutations and biochemical Wndings. The diVerential diagnosis of postnatal developmental delay should include free sialic acid storage disorders such as ISSD and Salla disease. Published by Elsevier Inc.
“…However, Lemyre et al (1999) showed that a nephrotic syndrome occurred in four of seven ISSD patients in whom renal evaluation was performed, and ISSD seems to be an important cause of nephrosis in infants with a storage disorder phenotype.…”
We report the first Japanese case of Salla disease. A 5-year-old male patient developed unique proteinuria with other clinical manifestations, including coarse facies, dysostosis multiplex, mild mitral valve regurgitation, umbilical and inguinal herniation, and mild developmental delay. Pathological analysis of biopsied kidney tissues showed marked vacuolation of podocytes, mesangial cells, capillary endothelial cells, and tubular cells. Biochemical studies involving thinlayer chromatography and mass spectrometry revealed increased excretion of free sialic acid (N-acetylneuraminic acid) into the patient's urine. Immuno-and lectin staining of the patient's cells demonstrated the accumulation of sialyl and asialyl glycoconjugates in lysosomes and late endosomes. A defect in sialyl glycoconjugate metabolism is thought to have occurred in the patient's cells, besides impairment of the lysosomal transport of free sialic acid residues. A renal disorder should be considered as an important manifestation, not only in infantile free sialic acid storage disease but also in Salla disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.